CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1 G93A mice with a C57BL/6 background

Abstract The synthetic copper-containing compound, CuATSM, has emerged as one of the most promising drug candidates developed for the treatment of amyotrophic lateral sclerosis (ALS). Multiple studies have reported CuATSM treatment provides therapeutic efficacy in various mouse models of ALS without...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jeremy S. Lum, Mikayla L. Brown, Natalie E. Farrawell, Luke McAlary, Diane Ly, Christen G. Chisholm, Josh Snow, Kara L. Vine, Tim Karl, Fabian Kreilaus, Lachlan E. McInnes, Sara Nikseresht, Paul S. Donnelly, Peter J. Crouch, Justin J. Yerbury
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/c146cd7fdab24b4d90091d3aa58e739c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!